ABSTRACT Colorectal cancer (CRC) holds third place in the global ranking of malignancies worldwide. Patients with CRC commonly show distinct outcomes and treatment responses due to their biological features and tumoral biomarkers. This review explores the repertoire of molecular biomarkers in CRC, comprised of chromosomal aberrations and genomic instability and...
ABSTRACT Objectives: Osimertinib is a third-generation EGFR inhibitor with activity against both sensitizing and resistance mutations. Following results of the phase III study, AURA3, which led to the approval of osimertinib worldwide, we have conducted ASTRIS with the aim of confirming the efficacy and safety of osimertinib. Methods: This is a phase...
